Bellicum Pharmaceuticals (NASDAQ:BLCM) Stock Crosses Above Fifty Day Moving Average of $0.08

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)’s stock price crossed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $0.08 and traded as high as $0.09. Bellicum Pharmaceuticals shares last traded at $0.07, with a volume of 6,000 shares changing hands.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on shares of Bellicum Pharmaceuticals in a report on Tuesday. They set a “sell” rating for the company.

Bellicum Pharmaceuticals Stock Down 6.6 %

The firm’s fifty day moving average is $0.08 and its 200-day moving average is $0.14.

Institutional Investors Weigh In On Bellicum Pharmaceuticals

A hedge fund recently bought a new stake in Bellicum Pharmaceuticals stock. HRT Financial LP acquired a new position in shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 36,470 shares of the biopharmaceutical company’s stock, valued at approximately $26,000. HRT Financial LP owned 0.42% of Bellicum Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 4.93% of the company’s stock.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen.